Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure
Aim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods. All adult Russian patients with NYHA class II-IV...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2022-01-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4800 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849341462276210688 |
|---|---|
| author | M. V. Zhuravleva S. N. Tereshchenko I. V. Zhirov S. V. Villevalde T. V. Marin Yu. V. Gagarina |
| author_facet | M. V. Zhuravleva S. N. Tereshchenko I. V. Zhirov S. V. Villevalde T. V. Marin Yu. V. Gagarina |
| author_sort | M. V. Zhuravleva |
| collection | DOAJ |
| description | Aim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods. All adult Russian patients with NYHA class II-IV HFrEF (left ventricular ejection fraction ≤40%) were considered as the target population. The characteristics of patients in the study corresponded to those in the Russian Hospital HF Registry (RUS-HFR). The study suggests that the use of dapagliflozin in addition to standard therapy will be expanded by 10% of the patient population annually in 2022-24. Cardiovascular mortality modeling was performed based on the extrapolation of DAPA-HF study result. The number of deaths that can be prevented was calculated when using dapagliflozin in addition to standard therapy. Further, the contribution of prevented deaths with dapagliflozin therapy to the achievement of federal and regional cardiovascular mortality target indicators (1, 2 and 3 years) was calculated.Results. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF with the expansion of dapagliflozin therapy by 10% of the patient population annually will additionally prevent 1729 cardiovascular death in the first year. This will ensure the implementation of cardiovascular mortality target indicators in Russia in 2022 by 11,8%. In the second year, 3769 cardiovascular deaths will be prevented, which will ensure the implementation of target indicators in 2023 by 17,2%. In the third year, 5465 cardiovascular deaths prevented, which will ensure the implementation of implementation of target indicators in 2024 by 18,7%.Conclusion. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF will ensure the implementation of implementation of target indicators in 2024 by 18,7%. |
| format | Article |
| id | doaj-art-a6b33c8db5a540299968419bb86339f8 |
| institution | Kabale University |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2022-01-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-a6b33c8db5a540299968419bb86339f82025-08-20T03:43:37Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202022-01-01261210.15829/1560-4071-2021-48003445Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failureM. V. Zhuravleva0S. N. Tereshchenko1I. V. Zhirov2S. V. Villevalde3T. V. Marin4Yu. V. Gagarina5Scientific Center for Expert Evaluation of Medicinal Products; I.M. Sechenov First Moscow State Medical UniversityNational Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional EducationNational Medical Research Center of Cardiology; Russian Medical Academy of Continuous Professional EducationAlmazov National Medical Research CenterI.M. Sechenov First Moscow State Medical UniversityI.M. Sechenov First Moscow State Medical UniversityAim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods. All adult Russian patients with NYHA class II-IV HFrEF (left ventricular ejection fraction ≤40%) were considered as the target population. The characteristics of patients in the study corresponded to those in the Russian Hospital HF Registry (RUS-HFR). The study suggests that the use of dapagliflozin in addition to standard therapy will be expanded by 10% of the patient population annually in 2022-24. Cardiovascular mortality modeling was performed based on the extrapolation of DAPA-HF study result. The number of deaths that can be prevented was calculated when using dapagliflozin in addition to standard therapy. Further, the contribution of prevented deaths with dapagliflozin therapy to the achievement of federal and regional cardiovascular mortality target indicators (1, 2 and 3 years) was calculated.Results. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF with the expansion of dapagliflozin therapy by 10% of the patient population annually will additionally prevent 1729 cardiovascular death in the first year. This will ensure the implementation of cardiovascular mortality target indicators in Russia in 2022 by 11,8%. In the second year, 3769 cardiovascular deaths will be prevented, which will ensure the implementation of target indicators in 2023 by 17,2%. In the third year, 5465 cardiovascular deaths prevented, which will ensure the implementation of implementation of target indicators in 2024 by 18,7%.Conclusion. The use of dapagliflozin in addition to standard therapy for patients with NYHA class II-IV CHrEF will ensure the implementation of implementation of target indicators in 2024 by 18,7%.https://russjcardiol.elpub.ru/jour/article/view/4800dapagliflozinheart failure with reduced ejection fractiontarget indicatorsmortality from circulatory system diseasesstate program “development of healthcare”federal project “fight against cardiovascular diseases” |
| spellingShingle | M. V. Zhuravleva S. N. Tereshchenko I. V. Zhirov S. V. Villevalde T. V. Marin Yu. V. Gagarina Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure Российский кардиологический журнал dapagliflozin heart failure with reduced ejection fraction target indicators mortality from circulatory system diseases state program “development of healthcare” federal project “fight against cardiovascular diseases” |
| title | Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure |
| title_full | Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure |
| title_fullStr | Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure |
| title_full_unstemmed | Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure |
| title_short | Effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure |
| title_sort | effect of dapagliflozin therapy on achieving cardiovascular mortality target indicators in patients with heart failure |
| topic | dapagliflozin heart failure with reduced ejection fraction target indicators mortality from circulatory system diseases state program “development of healthcare” federal project “fight against cardiovascular diseases” |
| url | https://russjcardiol.elpub.ru/jour/article/view/4800 |
| work_keys_str_mv | AT mvzhuravleva effectofdapagliflozintherapyonachievingcardiovascularmortalitytargetindicatorsinpatientswithheartfailure AT sntereshchenko effectofdapagliflozintherapyonachievingcardiovascularmortalitytargetindicatorsinpatientswithheartfailure AT ivzhirov effectofdapagliflozintherapyonachievingcardiovascularmortalitytargetindicatorsinpatientswithheartfailure AT svvillevalde effectofdapagliflozintherapyonachievingcardiovascularmortalitytargetindicatorsinpatientswithheartfailure AT tvmarin effectofdapagliflozintherapyonachievingcardiovascularmortalitytargetindicatorsinpatientswithheartfailure AT yuvgagarina effectofdapagliflozintherapyonachievingcardiovascularmortalitytargetindicatorsinpatientswithheartfailure |